Skip to content
Eleven years after the first CRISPR patent was filed, we’re anticipating what could be the first approval of a gene therapy based on CRISPR: […]
‘How do you price a cure?’ and other questions about the CRISPR era Read More »
In his State of the Union speech last night, President Joe Biden hailed the end of the COVID-19 emergency while ignoring the contribution of
State of the Union: Biden’s remarks on drug price controls and biomedical innovation Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
“I think we’re in a very exciting time in healthcare and biotech,” said Steven Ladd, Director of Business Development and Acquisitions at AbbVie. “It’s
China-U.S. biotech ventures are where collaboration meets competition Read More »
The narrative is that it’s a bad market for biotech, but CEOs and investors told a packed house at the 2023 BIO CEO and
Are SPACs dead? – and other questions about the biotech market outlook Read More »
On Day 1 of the BIO CEO and Investor Conference, a panel—Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period—brought together experts to look at
5 things to know about clinical trials Read More »
With the 118th Congress picking up steam, the Biotechnology Innovation Organization’s (BIO) Federal Government Relations team shared what to expect in health care and
What BIO’s watching on health care and agriculture policy in 2023 Read More »
“It’s exciting times,” said Kathy Fernando, Senior Vice President and Global Head of the Partner of Choice Organization at Pfizer Inc. Speaking about the
Pfizer Ignite’s new model is turning heads and sharing the wealth Read More »
David Thomas and Chad Wessel of the Biotechnology Innovation Organization’s (BIO) Industry Analysis team, authors of The State of Innovation in Pain and Addiction,
Investment in new pain and addiction treatments falls short, says BIO study Read More »
